1 of 1
Story summary
- The U.S. Food and Drug Administration will complete its mifepristone safety review in March 2027.
- The agency expects to receive study results by mid-December 2026.
- The study will compare mifepristone adverse-event rates with surgical abortions using data from about 100,000 women.
- Health Secretary Robert F. Kennedy Jr. ordered the review after a conservative think-tank claimed higher complication rates.